← All diseases
Cancer
Lung cancer (non-small cell)
Do you want to receive a message when there is new research on Lung cancer (non-small cell)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research about Lung cancer (non-small cell) is available. View what Premium costs.
Publications and studies (3193)
- Gut microbiota-associated nutritional-immune status predicts prognosis in postoperative NSCLC patients. (2026/12/31) ♡
- Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response. (2026/12/31) ♡
- Letter regarding 'clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring SMARCA4 mutations'. (2026/12/01) ♡
- Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRAS(G12C) and modulating the KRAS/AKT/ERK signaling axis. (2026/09/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Innovative immune checkpoint modulators: monoclonal antibodies, small molecules, non-coding RNAs, and nanoparticles in cancer immunotherapy. (2026/09/01) ♡
- Feasibility of routine clinical liquid-based cytology for lung cancer compact panel testing. (2026/09/01) ♡
- Systemic inflammatory response and complications developing in patients undergoing lobectomy for non-small-cell lung cancer: thoracotomy versus video-assisted thoracoscopic surgery. (2026/09/01) ♡
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. (2026/08/18) ♡
- KA-TMoE: A Deep Learning Method Using Time-Series CT Radiomics to Predict Post-Radiotherapy Rib Fractures in NSCLC Patients. (2026/08/10) ♡
- Novel Perfluoroalkyl Substance GenX exposure promotes non-small cell lung cancer progression by regulating the OTUB1/STAT3/VEGF axis. (2026/08/10) ♡
- Retraction notice to "YBX1 regulated by Runx3-miR-148a-3p axis facilitates non-small-cell lung cancer progression" [Cellular Signalling 85 (2021) 110049]. (2026/08/10) ♡
- Oncological Outcomes of Segmentectomy for Centrally Located Small-Sized Non-small-cell Lung Cancer: A Multicenter Study (CReGYT-02 Study). (2026/08/10) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Primed to React: Neutrophil-To-Lymphocyte Ratio to Predict Severe Checkpoint Inhibitor Pneumonitis. (2026/08/10) ♡
- Durvalumab Consolidation After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety. (2026/08/10) ♡
- Construction of a survival prediction model and analysis of influencing factors for brain metastasis in non-small cell lung cancer based on multi‑parameter clinical data. (2026/08/10) ♡
- Is There Still Room for Monotherapy in EGFR-Mutated Non-Small Cell Lung Cancer? (2026/08/10) ♡
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. (2026/08/10) ♡
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations: Research Summary. (2026/08/10) ♡
- Liquid Biopsies for Cancer: A Translational Science Review. (2026/08/10) ♡
- Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. (2026/08/10) ♡
- MAGEA1 drives tumor progression via activation of the AKT pathway and correlates with elevated radiosensitivity in lung adenocarcinoma. (2026/08/10) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. From KRAS inhibition to tumor adaptation: mechanistic layers of resistance and therapeutic strategies. (2026/08/09) ♡
- Arsenic-responsive hsa_circ_0000118 couples early stress granule dynamics to later NF-κB-related signaling adaptation in NSCLC. (2026/08/08) ♡
- Siglec-15 and PD-1 checkpoint blockade in combination with oncolytic Zika virus infection confers protection against immune-resistant gliomas. (2026/08/08) ♡
- Real-World Outcomes of Consolidation Durvalumab After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Cohort Study From Vietnam. (2026/08/08) ♡
- Exploring multidimensional cfDNA methylation fragmentomics for non-invasive postoperative assessment in early-stage lung cancer. (2026/08/08) ♡
- Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients Receiving Immune Checkpoint Inhibitors: A Pan-Tumor Propensity-Matched Analysis. (2026/08/08) ♡
- Salidroside Alleviates Mobocertinib-Induced Cardiotoxicity by Improving Cardiac Electrophysiology. (2026/08/08) ♡
- Clinical relative biological effectiveness of carbon-ion versus photon radiotherapy derived from tumor control probability models in locally advanced non-small cell lung cancer. (2026/08/08) ♡
- Lactate derived from CAFs mediates H3K18la in stemness gene promoters, which promotes tumor malignant phenotype formation. (2026/08/07) ♡
- Five-Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient-Initiated Nationwide Survey in Japan. (2026/08/07) ♡
- Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer. (2026/08/07) ♡
- A Transgenic mouse tolerant to syngeneic cancer cells expressing truncated human epidermal growth factor receptor. (2026/08/07) ♡
- EZH1/2 inhibition selectively targets SMARCA4/2 co-deficient lung cancer cells by suppressing stemness and proliferation. (2026/08/07) ♡
- Artificial intelligence-powered evaluation of the pathologic response to preoperative therapy in non-small cell lung cancer. (2026/08/07) ♡
- [Rescue Resections in Thoracic Surgery for Septic Lung Carcinomas Undergoing Systemic Therapy: a Case Series]. (2026/08/07) ♡
- Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. (2026/08/07) ♡
- Clonal LIMD1 loss drives PD-L1 immune evasion via ARIH1-dependent ubiquitination in lung cancer. (2026/08/07) ♡
- Immune signatures in NSCLC associated pleural effusions and implications for prognosis. (2026/08/07) ♡
- Efficacy and Safety of Sintilimab in Combination With Anlotinib and Chemoradiotherapy as First-Line Treatment for Driver Gene-Negative Oligometastatic Non-small Cell Lung Cancer: A Real-World Cohort Study. (2026/08/07) ♡
- Diabetes Increases Immunotherapy-Related Toxicity but Not Efficacy in Metastatic Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. (2026/08/06) ♡
- Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC. (2026/08/06) ♡
- Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer. (2026/08/06) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. (2026/08/06) ♡
- SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation. (2026/08/06) ♡
- Hypoxia-activated endothelial cells drive stemness and vasculogenic mimicry in NSCLC via a HIF-1α/ITPR3 axis. (2026/08/06) ♡
- De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study. (2026/08/06) ♡
- Preoperative prognostic nutritional index predicts overall survival in surgically resected small cell lung cancer: A single-institution experience. (2026/08/06) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Pooled safety profiles of bispecific antibodies targeting PD-1/CTLA-4 or PD-1/VEGF in non-small cell lung cancer: a systematic review and single-arm meta-analysis. (2026/08/05) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. (2026/08/05) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.